Skip to main content
SpringerLink
Log in

Abciximab to become routine adjunct to PTCA in acute MI?

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

It will soon become common practice for cardiologists to use glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists as adjunctive therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (MI), predicts Dr Eric Topol from the Cleveland Clinic, Ohio, US. His comments followed the presentation of the RAPPORT * study results, which showed that administering the GPIIb/IIIa receptor antagonist abciximab to patients undergoing PTCA for acute MI led to a 74% reduction in the composite endpoint of death, recurrent MI and repeat target vessel revascularisation, compared with placebo. The data were presented at the 19th Congress of the European Society of Cardiology [ Stockholm, Sweden; August 1997 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Gill Higgins
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

* ReoPro in Acute Myocardial Infarction and Primary PTCA Organisation and Randomised Trial

Rights and permissions

Reprints and permissions

About this article

Cite this article

Higgins, G. Abciximab to become routine adjunct to PTCA in acute MI?. Inpharma Wkly. 1103, 11–12 (1997). https://doi.org/10.2165/00128413-199711030-00023

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199711030-00023

Keywords

Search

Navigation